The androgen receptor in health and disease

Annual Review of Physiology

Volumn 75, Issue , 2013, Pages 201-224

  Matsumoto, Takahiro ^a   Sakari, Matomo ^a   Okada, Maiko ^b   Yokoyama, Atsushi ^b   Takahashi, Sayuri ^b   Kouzmenko, Alexander ^b,c   Kato, Shigeaki ^d,e  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e Soma Central Hospital   (Japan)

Author keywords

Coregulator; Premature ovarian failure; Prostate cancer; Reproduction

Indexed keywords

ANDROGEN RECEPTOR;

ALPHA HELIX; ANDROGEN INSENSITIVITY SYNDROME; CHROMATIN; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; NUCLEOSOME; OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN STRUCTURE; REVIEW; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION; SPERMATOGENESIS;

ANDROGENS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; MICE; RECEPTORS, ANDROGEN; REPRODUCTIVE HEALTH; SIGNAL TRANSDUCTION;

EID: 84873616329     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-030212-183656     Document Type: Review

References (156)

1. Mooradian AD, Morley JE, Korenman SG. 1987. Biological actions of androgens. Endocr. Rev. 8:1-28
2. Wilson JD. 1999. The role of androgens in male gender role behavior. Endocr. Rev. 20:726-37
3. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, et al. 2008. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299:39-52
4. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79
5. Zitzmann M. 2009. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat. Rev. Endocrinol. 5:673-81
6. McCarthy N. 2011. Prostate cancer: studying the classics. Nat. Rev. Cancer 11:386-87
7. Mitchell F. 2012. Reproductive endocrinology: testosterone metabolite nonessential for androgen effects. Nat. Rev. Endocrinol. 8:256
8. Larsson R, Mongan NP, Johansson M, Shcherbina L, Abrahamsson PA, et al. 2011. Clinical trial update and novel therapeutic approaches for metastatic prostate cancer. Curr. Med. Chem. 18:4440-53
9. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. 1988. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327-30
10. Sen A, Prizant H, Hammes SR. 2011. Understanding extranuclear (nongenomic) androgen signaling: what a frog oocyte can tell us about human biology. Steroids 76:822-28
11. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, et al. 2004. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc. Natl. Acad. Sci. USA 101:1327-32
12. Holdcraft RW, Braun RE. 2004. Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids. Development 131:459-67
13. Kato S. 2002. Androgen receptor structure and function from knock-out mouse. Clin. Pediatr. Endocrinol. 11:1-7
14. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD. 2005. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. J. Mol. Endocrinol. 35:547-55
15. Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H, et al. 2002. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc. Natl. Acad. Sci. USA 99:13498-503
16. Narayanan R, Jiang J, Gusev Y, Jones A, Kearbey JD, et al. 2010. MicroRNAs are mediators of androgen action in prostate and muscle. PLoS ONE 5:e13637
17. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, et al. 1995. The nuclear receptor super-family: the second decade. Cell 83:835-39
18. Heemers HV, Tindall DJ. 2007. Androgen receptor(AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778-808
19. Bennett N, Hooper JD, Lee CS, Gobe GC. 2009. Androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 61:961-70
20. Lamont KR, Tindall DJ. 2011. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol. Endocrinol. 25:897-907
21. McKenna NJ, Cooney AJ, DeMayo FJ, Downes M, Glass CK, et al. 2009. Minireview: evolution of NURSA, the nuclear receptor signaling atlas. Mol. Endocrinol. 23:740-46
22. Haile S, Sadar MD. 2011. Androgen receptor and its splice variants in prostate cancer. Cell Mol. Life Sci. 68:3971-81
23. Yap TA, Zivi A, Omlin A, de Bono JS. 2011. The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8:597-610
24. Prescott J, Coetzee GA. 2006. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 231:12-19
25. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. 2009. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-90
26. Ma ZQ, Liu Z, Ngan ES, Tsai SY. 2001. Cdc25B functions as a novel coactivator for the steroid receptors. Mol. Cell. Biol. 21:8056-67
27. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, et al. 2000. Cyclin E as a coactivator of the androgen receptor. J. Cell Biol. 150:873-80
28. He B, Gampe RT Jr, Kole AJ, Hnat AT, Stanley TB, et al. 2004. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16:425-38
29. Moras D, Gronemeyer H. 1998. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10:384-91
30. Kishimoto M, Fujiki R, Takezawa S, Sasaki Y, Nakamura T, et al. 2006. Nuclear receptor mediated gene regulation through chromatin remodeling and histone modifications. Endocr. J. 53:157-72
31. Anbalagan M, Huderson B, Murphy L, Rowan BG. 2012. Post-translational modifications of nuclear receptors and human disease. Nucl. Recept. Signal. 10:e001
32. Huang P, Chandra V, Rastinejad F. 2010. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 72:247-72
33. Centenera MM, Harris JM, Tilley WD, Butler LM. 2008. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 22:2373-82
34. MacLean HE, Warne GL, Zajac JD. 1997. Localization of functional domains in the androgen receptor. J. Steroid Biochem. Mol. Biol. 62:233-42
35. Tan M, Luo H, Lee S, Jin F, Yang JS, et al. 2011. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146:1016-28
36. Fu M, Rao M, Wang C, Sakamaki T, Wang J, et al. 2003. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell. Biol. 23:8563-75
37. Moore RL, Dai Y, Faller DV. 2012. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J. Endocrinol. 213:37-48
38. Yang Y, Tse AK, Li P, Ma Q, Xiang S, et al. 2011. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 30:2207-18
39. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, et al. 2011. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol. Cancer Ther. 10:1644-55
40. Xu J, Wu RC, O'Malley BW. 2009. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 9:615-30
41. Huang ZQ, Li J, Sachs LM, Cole PA, Wong J. 2003. A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription. EMBO J. 22:2146-55
42. Montie HL, Pestell RG, Merry DE. 2011. SIRT1 modulates aggregation and toxicity through deacety-lation of the androgen receptor in cell models of SBMA. J. Neurosci. 31:17425-36
43. Zhou VW, Goren A, Bernstein BE. 2011. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12:7-18
44. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, et al. 2007. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9:347-53
45. I controls demethylation at histone H3K4. Nature 464:792-6
46. Ko S, Ahn J, Song CS, Kim S, Knapczyk-Stwora K, Chatterjee B. 2011. Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase. Mol. Endocrinol. 25:433-44
47. Gaughan L, Stockley J, Wang N, McCracken SR, Treumann A, et al. 2011. Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res. 39:1266-79
48. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW. 2010. Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol. Cell. Biol. 30:5260-72
49. Batta K, Zhang Z, Yen K, Goffman DB, Pugh BF. 2011. Genome-wide function of H2B ubiquitylation in promoter and genic regions. Genes Dev. 25:2254-65
50. Jääskeläinen T, Makkonen H, Visakorpi T, Kim J, Roeder RG, Palvimo JJ. 2012. Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. Mol. Cell. Endocrinol. 350:87-98
51. Zhu P, Zhou W, Wang J, Puc J, Ohgi KA, et al. 2007. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol. Cell 27:609-21
52. Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM. 2011. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J. 30:468-79
53. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, et al. 2009. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15:270-82
54. Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, et al. 2008. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res. 68:4551-58
55. Shen H, Powers N, Saini N, Comstock CE, Sharma A, et al. 2008. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 68:10154-62
56. Menon T, Yates JA, Bochar DA. 2010. Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. Mol. Endocrinol. 24:1165-74
57. Smith CL, O'Malley BW. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71
58. McPhaul MJ. 1999. Molecular defects of the androgen receptor. J. Steroid Biochem. Mol. Biol. 69:315-22
59. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS. 1995. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16:271-321
60. Bardin CW, Bullock L, Schneider G, Allison JE, Stanley AJ. 1970. Pseudohermaphrodite rat: end organ insensitivity to testosterone. Science 167:1136-37
61. Lyon MF, Hawkes SG. 1970. X-linked gene for testicular feminization in the mouse. Nature 227:1217-19
62. Schultz MG. 1962. Male pseudohermaphroditism diagnosed with aid of sex chromatin technique. J. Am. Vet. Med. Assoc. 140:241-44
63. Meyers-Wallen VN, Wilson JD, Griffin JE, Fisher S, Moorhead PH, et al. 1989. Testicular feminization in a cat. J. Am. Vet. Med. Assoc. 195:631-34
64. Pasello-Legrand F, Mowat V. 2004. Two cases of spontaneous pseudohermaphroditism in Cynomolgus monkeys (Macaca fascicularis). J. Vet. Med. A Physiol. Pathol. Clin. Med. 51:344-47
65. Gaspar ML, Meo T, Bourgarel P, Guenet JL, Tosi M. 1991. A single base deletion in the Tfm androgen receptor gene creates a short-lived messenger RNA that directs internal translation initiation. Proc. Natl. Acad. Sci. USA 88:8606-10
66. Verhoeven G, Willems A, Denolet E, Swinnen JV, De Gendt K. 2010. Androgens and spermatogenesis: lessons from transgenic mouse models. Philos. Trans. R. Soc. Lond. Ser. B 365:1537-56
67. Walters KA, Simanainen U, Handelsman DJ. 2010. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum. Reprod. Update 16:543-58
68. Wang RS, Yeh S, Tzeng CR, Chang C. 2009. Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr. Rev. 30:119-32
69. Tsai MY, Yeh SD, Wang RS, Yeh S, Zhang C, et al. 2006. Differential effects of spermatogenesis and fertility in mice lacking androgen receptor in individual testis cells. Proc. Natl. Acad. Sci. USA 103:18975-80
70. Chang C, Chen YT, Yeh SD, Xu Q, Wang RS, et al. 2004. Infertility with defective spermatogenesis and hypotestosteronemia in male mice lacking the androgen receptor in Sertoli cells. Proc. Natl. Acad. Sci. USA 101:6876-81
71. Lim P, Robson M, Spaliviero J, McTavish KJ, Jimenez M, et al. 2009. Sertoli cell androgen receptor DNA binding domain is essential for the completion of spermatogenesis. Endocrinology 150:4755-65
72. Willems A, Batlouni SR, Esnal A, Swinnen JV, Saunders PT, et al. 2010. Selective ablation of the androgen receptor in mouse Sertoli cells affects Sertoli cell maturation, barrier formation and cytoskeletal development. PLoS ONE 5(11):e14168
73. Xu Q, Lin HY, Yeh SD, Yu IC, Wang RS, et al. 2007. Infertility with defective spermatogenesis and steroidogenesis in male mice lacking androgen receptor in Leydig cells. Endocrine 32:96-106
74. Welsh M, Saunders PT, Atanassova N, Sharpe RM, Smith LB. 2009. Androgen action via testicular peritubular myoid cells is essential for male fertility. FASEB J. 23:4218-30
75. Arnold AP, Gorski RA. 1984. Gonadal steroid induction of structural sex differences in the central nervous system. Annu. Rev. Neurosci. 7:413-42
76. Plapinger L, McEwen BS. 1978. Gonadal steroid-brain interactions in sexual differentiation. In Biological Determinants of Sexual Behaviour, ed. JB Hutchison, pp. 153-218. Chichester/New York: Wiley
77. Naftolin F, Ryan KJ, Davies IJ, Petro Z, Kuhn M. 1975. The formation and metabolism of estrogens in brain tissues. Adv. Biosci. 15:105-21
78. Matsumoto T, Honda S, Harada N. 2003. Alteration in sex-specific behaviors in male mice lacking the aromatase gene. Neuroendocrinology 77:416-24
79. Ogawa S, Lubahn DB, Korach KS, Pfaff DW. 1997. Behavioral effects of estrogen receptor gene disruption in male mice. Proc. Natl. Acad. Sci. USA 94:1476-81
80. Handa RJ, Weiser MJ, Zuloaga DG. 2009. A role for the androgen metabolite, 5α-androstane-3β, 17β-diol, in modulating oestrogen receptor β-mediated regulation of hormonal stress reactivity. J. Neuroen-docrinol. 21:351-58
81. Goldfoot DA, Van Der Werff Ten Bosch JJ. 1975. Mounting behavior of female guinea pigs after prenatal and adult administration of the propionates of testosterone, dihydrotestosterone, and androstanediol. Hormones Behav. 6:139-48
82. Sato T, Matsumoto T, Kawano H, Watanabe T, Uematsu Y, et al. 2004. Brain masculinization requires androgen receptor function. Proc. Natl. Acad. Sci. USA 101:1673-78
83. Matsumoto T, Inoue K, Sato T, Kato S. 2011. Genetic impact of both sex hormones in male-typical behaviors. Adv. Exp. Med. Biol. 707:125-26
84. Juntti SA, Tollkuhn J, Wu MV, Fraser EJ, Soderborg T, et al. 2010. The androgen receptor governs the execution, but not programming, of male sexual and territorial behaviors. Neuron 66:260-72
85. Raskin K, de Gendt K, Duittoz A, Liere P, Verhoeven G, et al. 2009. Conditional inactivation of androgen receptor geneinthe nervous system: effectsonmale behavioral and neuroendocrine responses. J. Neurosci. 29:4461-70
86. Kang HY, Shyr CR, Huang CK, Tsai MY, Orimo H, et al. 2008. Altered TNSALP expression and phosphate regulation contribute to reduced mineralization in mice lacking androgen receptor. Mol. Cell. Biol. 28:7354-67
87. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, et al. 2003. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. USA 100:9416-21
88. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, et al. 2009. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J. Bone Miner. Res. 24:621-31
89. Notini AJ, McManus JF, Moore A, Bouxsein M, Jimenez M, et al. 2007. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J. Bone Miner. Res. 22:347-56
90. Russell PK, Clarke MV, Skinner JP, Pang TP, Zajac JD, Davey RA. 2012. Identification of gene pathways altered by deletion of the androgen receptor specifically in mineralizing osteoblasts and osteocytes in mice. J. Mol. Endocrinol. 49:1-10
91. Denmeade SR, Isaacs JT. 2002. A history of prostate cancer treatment. Nat. Rev. Cancer 2:389-96
92. Hsieh AC, Small EJ, Ryan CJ. 2007. Androgen-response elementsinhormone- refractory prostate cancer: implications for treatment development. Lancet Oncol. 8:933-39
93. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1:34-45
94. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al. 1995. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9:401-6
95. Brooke GN, Parker MG, Bevan CL. 2008. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27:2941-50
96. Mueller MM, Fusenig NE. 2004. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4:839-49
97. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:1393-98
98. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, et al. 2006. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25:3905-13
99. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J. 1996. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29:153-58
100. Takahashi S, Watanabe T, Okada M, Inoue K, Ueda T, et al. 2011. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc. Natl. Acad. Sci. USA 108:4938-43
101. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, et al. 2005. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. USA 102:1151-56
102. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-48
103. Clark J, Attard G, Jhavar S, Flohr P, Reid A, et al. 2008. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27:1993-2003
104. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, et al. 2008. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 14:3380-85
105. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, et al. 2009. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139:1069-83
106. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, et al. 2009. Induced chromosomal proximity and gene fusions in prostate cancer. Science 326:1230
107. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, et al. 2008. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc. Natl. Acad. Sci. USA 105:12188-93
108. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. 2001. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene inprostate epithelium. Proc. Natl. Acad. Sci. USA 98:10823-28
109. Zhu C, Luong R, Zhuo M, Johnson DT, McKenney JK, et al. 2011. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J. Biol. Chem. 286:33478-88
110. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, et al. 2004. TGF-βsignaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-51
111. Karlou M, Tzelepi V, Efstathiou E. 2010. Therapeutic targeting of the prostate cancer microenviron-ment. Nat. Rev. Urol. 7:494-509
112. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, et al. 2006. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124:615-29
113. Leotoing L, Manin M, Monte D, Baron S, Communal Y, et al. 2007. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J. Mol. Endocrinol. 39:151-62
114. Kwabi-Addo B, Ozen M, Ittmann M. 2004. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer 11:709-24
115. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. 2006. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell Biochem. 99:392-401
116. Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA, Rowley DR. 2004. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-β1. Prostate 58:299-307
117. Yamamoto H, Oue N, Sato A, Hasegawa Y, Matsubara A, et al. 2010. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29:2036-46
118. Kennedy WR. 1968. The innervation of the human muscle spindle. Neurology 18:290
119. Abel A, Walcott J, Woods J, Duda J, Merry DE. 2001. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum. Mol. Genet. 10:107-16
120. Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. 2001. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum. Mol. Genet. 10:1039-48
121. Bingham PM, Scott MO, Wang S, McPhaul MJ, Wilson EM, et al. 1995. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nat. Genet. 9:191-96
122. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al. 2002. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843-54
123. Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, et al. 2006. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Investig. 116:2663-72
124. Monks DA, Johansen JA, Mo K, Rao P, Eagleson B, et al. 2007. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc. Natl. Acad. Sci. USA 104:18259-64
125. Ross CA. 1997. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19:1147-50
126. Yang W, Dunlap JR, Andrews RB, Wetzel R. 2002. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11:2905-17
127. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. 2005. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26:251-82
128. Kimura S, Matsumoto T, Matsuyama R, Shiina H, Sato T, et al. 2007. Androgen receptor function in folliculogenesis and its clinical implication in premature ovarian failure. Trends Endocrinol. Metab. 18:183-89
129. Walters KA, Allan CM, Handelsman DJ. 2008. Androgen actions and the ovary. Biol. Reprod. 78:380-89
130. Simpson ER. 2000. Role of aromatase in sex steroid action. J. Mol. Endocrinol. 25:149-56
131. Ehrmann DA, Barnes RB, Rosenfield RL. 1995. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr. Rev. 16:322-53
132. Horie K, Takakura K, Imai K, Liao S, Mori T. 1992. Immunohistochemical localization of androgen receptor in the human endometrium, decidua, placenta and pathological conditions of the endometrium. Hum. Reprod. 7:1461-66
133. Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smyth CD, Hillier SG. 1995. Developmental regulation of androgen receptor in rat ovary. J. Endocrinol. 145:535-43
134. Weil S, Vendola K, Zhou J, Bondy CA. 1999. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J. Clin. Endocrinol. Metab. 84:2951-56
135. Bagnell CA, Mills TM, Costoff A, Mahesh VB. 1982. A model for the study of androgen effects on follicular atresia and ovulation. Biol. Reprod. 27:903-14
136. Vendola KA, Zhou J, Adesanya OO, Weil SJ, Bondy CA. 1998. Androgens stimulate early stages of follicular growth in the primate ovary. J. Clin. Investig. 101:2622-29
137. Hu YC, Wang PH, Yeh S, Wang RS, Xie C, et al. 2004. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc. Natl. Acad. Sci. USA 101:11209-14
138. Shiina H, Matsumoto T, Sato T, Igarashi K, Miyamoto J, et al. 2006. Premature ovarian failure in androgen receptor-deficient mice. Proc. Natl. Acad. Sci. USA 103:224-29
139. Walters KA, McTavish KJ, Seneviratne MG, Jimenez M, McMahon AC, et al. 2009. Subfertile female androgen receptor knockout mice exhibit defects in neuroendocrine signaling, intraovarian function, and uterine development but not uterine function. Endocrinology 150:3274-82
140. Ohno S, Christian L, Attardi B. 1973. Role of testosterone in normal female function. Nat. New Biol. 243:119-20
141. Lyon MF, Glenister PH. 1974. Evidence from Tfm-O that androgen is inessential for reproduction in female mice. Nature 247:366-67
142. Sen A, Hammes SR. 2010. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol. Endocrinol. 24:1393-403
143. Laml T, Preyer O, Umek W, Hengstschlager M, Hanzal H. 2002. Genetic disorders in premature ovarian failure. Hum. Reprod. Update 8:483-91
144. Toniolo D. 2006. X-linked premature ovarian failure: a complex disease. Curr. Opin. Genet. Dev. 16:293-300
145. Matzuk MM, Burns KH, Viveiros MM, Eppig JJ. 2002. Intercellular communication in the mammalian ovary: Oocytes carry the conversation. Science 296:2178-80
146. Otsuka F, McTavish KJ, Shimasaki S. 2011. Integral role of GDF-9 and BMP-15 in ovarian function. Mol. Reprod. Dev. 78:9-21
147. Schlessinger D, Herrera L, Crisponi L, Mumm S, Percesepe A, et al. 2002. Genes and translocations involved in POF. Am. J. Med. Genet. 111:328-33
148. Simpson JL, Rajkovic A. 1999. Ovarian differentiation and gonadal failure. Am. J. Med. Genet. 89:186-200
149. Aarnisalo P, Palvimo JJ, Janne OA. 1998. CREB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. USA 95:2122-27
150. Ma H, Hong H, Huang SM, Irvine RA, Webb P, et al. 1999. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell. Biol. 19:6164-73
151. Sharma M, Zarnegar M, Li X, Lim B, Sun Z. 2000. Androgen receptor interacts with a novel MYST protein, HBO1. J. Biol. Chem. 275:35200-8
152. Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, et al. 2001. Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293:853-57
153. Chen D, Ma H, Hong H, Koh SS, Huang SM, et al. 1999. Regulation of transcription by a protein methyltransferase. Science 284:2174-77
154. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, et al. 2005. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-39
155. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, et al. 2006. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125:483-95
156. Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, et al. 2008. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat. Cell Biol. 10:53-60